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The signaling pathway of G protein-coupled receptors is strongly linked to their trafficking profile. Little is known about the molecular mechanisms involved in the vasopressin receptor V 1b subtype (V 1b R) trafficking and its impact on receptor signaling and regulation. For this purpose, we investigated the role of β-arrestins in receptor desensitization, internalization and recycling and attempted to dissect the V 1b R-mediated MAP kinase pathway. Using MEF cells Knockedout for β-arrestins 1 and 2, we demonstrated that both β-arrestins 1 and 2 play a fundamental role in internalization and recycling of V 1b R with a rapid and transient V 1b R-β-arrestin interaction in contrast to a slow and long-lasting β-arrestin recruitment of the V 2 vasopressin receptor subtype (V 2 R). Using V 1b R-V 2 R chimeras and V 1b R C-terminus truncations, we demonstrated the critical role of the V 1b R C-terminus in its interaction with β-arrestins thereby regulating the receptor internalization and recycling kinetics in a phosphorylation-independent manner. In parallel, V 1b R MAP kinase activation was dependent on arrestins and Src-kinase but independent on G proteins. Interestingly, Src interacted with hV 1b R at basal state and dissociated when receptor internalization occurred. Altogether, our data describe for the first time the trafficking profile and MAP kinase pathway of V 1b R involving both arrestins and Src kinase family.
K E Y W O R D S
arrestin, biased signaling, BRET, DERET, FRET, G-protein-coupled receptor (GPCR), intracellular trafficking, mitogen-activated protein kinase (MAPK), signal transduction, Src kinase, V 1b and V 2 
vasopressin receptors
The human V 1b vasopressin (AVP) receptor (hV 1b R) is widely distributed in the central nervous system and is a key regulator of the hypothalamic-pituitary-adrenal (HPA) axis through its involvement in the regulation of adrenocorticotropin (ACTH) release. 1, 2 This function highlights the potential of hV 1b R as a drug target for stress, anxiety and depression. 3 Although specific hV 1b R antagonist compounds, such as SR149415, are presently under clinical trials for treating these pathologies, 4 elucidating the molecular mechanisms involved in hV 1b R trafficking and signaling would provide a unique opportunity to better understand its regulation and develop new therapeutic agents.
AVP receptors are typical G protein-coupled receptors (GPCRs) and their activation leads to G protein-dependent and -independent pathways. 5 Arrestins are scaffolding proteins playing central roles in GPCR regulation and trafficking, such as internalization and recycling, but also in G protein-independent signaling pathways through the activation of mitogen-activated protein kinases (MAPKs). 6 By contrast to human V 1a (hV 1a R) and V 2 (hV 2 R) AVP receptors for which internalization, recycling and signaling processes are well documented, [7] [8] [9] [10] [11] little is known about hV 1b R. It has long been demonstrated that hV 1b R is essentially coupled to Gαq 12 but more recently also to Gαs 13 and that internalization is mediated via clathrin-coated pits. 14 In addition, the activation of MAPKs by hV 1b R, characterized by the phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 proteins, was demonstrated to be pertussis toxin (PTX)-insensitive, but was dependent on the activation of phospholipase C and protein kinase C (PKC). This suggests the involvement of Gq. 15, 16 However, up to now, no link was evidenced between G protein coupling of hV 1b R, its trafficking, related scaffolding proteins and activation of MAPK pathways.
V 1a R and V 2 R are prototypic type A and B GPCR in terms of trafficking characterized by either rapid or slow internalization and recycling profiles through a transient or a long-lasting interaction with arrestins, respectively. These data evidence the major role of arrestins in the AVP GPCR family regulation. For both V 1a R and V 2 R, their cytoplasmic C-terminus (C-ter) is a key determinant for arrestin binding and respective trafficking profiles because C-ter V 2 truncations 17 or chimera constructions such as V 1a R-C-terV 2 R or β 2 -adrenoceptor-C-terV 2 R 7, 18 pointed out the V 2 C-terminal part as a fundamental region for arrestin interaction. As a prototype of GPCR-arrestin stable complex, the 3-dimensional structure of a chemically synthesized V 2 C-terminus phosphorylated peptide in complex with a purified arrestin-2 was recently solved giving us new insights into their molecular interactions. 19 Moreover, regarding the signaling pathways of the V 2 R, an unanticipated role for arrestins was discovered. Very interestingly, engagement of arrestins by the transactivated insulin-like growth factor receptor is needed for AVP to stimulate ERK1/2 activation via V 2 R. 20 In this study, we aimed at dissecting the molecular mechanisms . Using V 2 R as control, we focused on the potential role of the hV 1b R C-terminus and the scaffolding proteins arrestins in receptor internalization and recycling. We also investigated the potential involvement of G proteins, hV 1b R C-terminus, arrestins and Src kinase in MAPK activation. Our major findings identified β-arrestins as key players in hV 1b R trafficking, whereas arrestins and Src kinase family constitutes key targets for hV 1b R-related ERK phosphorylation signaling.
1 | RESULTS
| V 1b R internalization and recycling processes
First, we examined the internalization and recycling profiles of hV 1b R-WT in comparison with hV 2 R-WT. In a previous study, Pena Scatchard analysis (see section 3). Results are expressed as the mean AE SEM of percentage of control conditions from at least 3 independent experiments. For each condition, a statistical analysis between hV 1b R-WT as a control and hV 2 R-WT was done: *P < .05, **P < .01 and ***P < .001. C, SNAP-hV 1b R internalization induced by 100 nM AVP for a 50-minute incubation time followed by a 60-minute addition of either buffer ( ) or an excess of the antagonist SR149415
10 μM (↓) to stop receptor internalization and to induce receptor recycling ( ). Percent of ratios (620/520 nm) were plotted as a function of time and data represent mean AE SEM of an experiment representative of 3 carried out in triplicates. For each condition, a statistical analysis between the 2 conditions was done: *P < .05, **P < .01, ***P < .001 and no indication means no significant difference et al 23 have shown that hV 1b R internalizes upon AVP stimulation, but no correlation with arrestin interaction was investigated. As shown in Figure 1A , hV 1b R internalized more rapidly than hV 2 R at 30 C with t 1/2 values of 3.8 AE 0.6 and 9.8 AE 2.1 minutes for hV 1b R and hV 2 R, respectively (Table 3) . For both receptors, similar levels of binding sites were still at the cell surface after 45 minutes of exposure with 100 nM AVP. In another set of experiments performed at 37 C, we evaluated the capacity of the 2 receptors to recycle to the plasma membrane ( Figure 1B ; Table 3 ). Cells were first stimulated with 100 nM AVP for 20 minutes and after washing, the cell surface binding sites were measured at different periods of recycling. As shown in Figure 1B , hV 1b R and hV 2 R behaved differently because hV 1b R recycled very rapidly to the cell surface. Thus, 100% AE 7% and 129% AE 11% of binding sites were measured after 30-and 120-minute recycling periods, respectively, as compared to cells not treated with AVP. By contrast, hV 2 R did not recycle (34% AE 6% and 50% AE 5% surface receptors after 30 and 120 minutes, respectively).
To demonstrate that the majority of hV 1b R surface recovery is due to recycling or to de novo biosynthesis of hV 1b R, we evaluated receptor internalization and recycling by the above strategy using a protein synthesis inhibitor, cycloheximide or by an alternative strategy, the diffusion-enhanced resonance energy transfer (DERET) method. 24 Cycloheximide (500 μM), a protein synthesis inhibitor, did not modulate surface receptor sites except for a 120-minute recycling time for which it induced a decrease of 21% AE 3% of cell surface receptors compared to cycloheximide nontreated cells. These results suggest that de novo receptor synthesis probably only affects receptor surface levels at long recycling time points (data not shown).
Moreover, we used, the SNAP-tagged-hV 1b R construction that can be covalently labeled with SNAP-Lumi4-Tb showing specifically the surface receptors. By using this strategy, only SNAP-hV 1b R present at the cell surface, but not receptor trapped in intracellular compartments or neosynthesized, are labeled. As shown in Figure 1C , activation of hV 1b R resulted in the fluorescence resonance energy transfer (FRET) ratio increase, proving a fast hV 1b R internalization. By contrast, adding the specific V 1b R antagonist, SR149415 resulted in a very rapid and dramatic decrease of the FRET ratio. These results indicate that all the labeled internalized hV 1b R receptors recycled back to the membrane proving the existence of a very efficient hV 1b R recycling. Interestingly, when blocking hV 1b R internalization with the antagonist, recycling occurs in less than 30 minutes, a time in complete agreement with recycling kinetics shown in Figure 1A ,B.
Therefore, compared to V 2 R, a class B GPCR (slow internalization and recycling rates), hV 1b R can indeed be classified as a class A receptor (rapid internalization and recycling processes). These data were confirmed by binding and confocal microscopy image analysis in the pituitary AtT20 cell line stably expressing hV 1b R-EGFP in which the receptor presented an equivalent internalization-recycling pattern ( Figure 11A and Video S1).
| Role of arrestins in hV 1b R internalization process
To evidence the role of arrestins in hV 1b R trafficking process, we transfected hV 1b R-WT in the MEF cell line, knocked-out for one or the other arrestin (MEF KO β-arrestin-1; MEF KO β-arrestin-2) or for both (MEF KO β-arrestin-1/2). As shown in Figure 2A ,B and β-arrestin-1/2), hV 1b R internalization was drastically inhibited to a residual fraction ( Figure 2C and Table 1 ). Taken together, these observations clearly demonstrate the importance of both β-arrestin 1 and 2 in hV 1b R internalization.
| Receptor-arrestin interaction profile
In order to assess the direct physical interaction between hV 1b R and arrestins in real-time and live cells, we used a BRET approach with a hV 1b R tagged at the C-terminus with Renilla luciferase (hV 1b R-Rluc) and the β-arrestin 1 or 2 tagged with the yellow fluorescent protein (β-arrestin-YFP). As shown in Table 3 , hV 1b R-Rluc is comparable to hV 1b R-WT regarding the AVP binding properties, the induction of Ca Figure 3F ). In addition, the interaction between hV 1b RRluc and β-arrestin 1 or 2 was confirmed by co-immunoprecipitation using 6Myc-tagged-hV 1b R which exhibits similar pharmacological properties as hV 1b -WT (Table 4) In parallel, confocal microscopy and image analysis in the AtT20 cell line stably expressing hV 1b R-EGFP and transfected with β-arrestin-Flag confirmed the mobilization of arrestins to the plasma membrane where colocalization with receptor occurs and leads to subsequent internalization in endosomes ( Figure 11B ).
| Receptor C-terminus involvement in arrestin recruitment
To investigate the involvement of the hV 1b R C-terminus in the interaction with β-arrestins, a domain that has been shown to be crucial for β-arrestin recruitment in many GPCRs, we took advantage of the differences between V 1b and V 2 receptors. Indeed, we compared the profile of arrestin recruitment, receptor internalization and recycling of hV 1b R with those of hV 2 R or of their chimeras in which respective C-termini have been exchanged (hV 1b R-CterV 2 R and hV 2 R-CterV 1b R) ( Table 2 ). The chimeras displayed similar binding and G proteincoupling properties as compared to the wild-type (WT) receptors from which they were derived (Table 3) . By contrast, the kinetic patterns of β-arrestin recruitment, receptor internalization and recycling were totally related to the receptor C-termini from which they originated ( Figure 5A,B) . Indeed, hV 1b R-CterV 2 R-Rluc could interact with β-arrestin-1-YFP in a slow and long-lasting manner similar to that of hV 2 R-Rluc. On the contrary, hV 2 R-CterV 1b R-Rluc interacted with β-arrestin-1-YFP in a rapid and transient manner as hV 1b R-Rluc did.
Consistently, internalization kinetics were similar between hV 1b RCterV 2 R and hV 2 R-WT (t 1/2 of 7.6 AE 1.1 and 9.8 AE 2.1 minutes, respectively) on the one hand. They were also very similar between hV 2 R-CterV 1b R and hV 1b R-WT (t 1/2 of 2.7 AE 0.5 and 3.8 AE 0.6 minutes, respectively) on the other hand, but significantly different between the 2 groups ( Figure 5C ,D). For both chimeras, similar levels of binding sites were still present at the cell surface after a 45-minute exposure, at 30 C (40% AE 3% and 36% AE 2% for hV 2 R-CterV 1b R and hV 1b R-CterV 2 R, respectively). This is similar to what we observed for WT receptors (34% AE 2% and 35% AE 4% for hV 1b R-WT and hV 2 R-WT, respectively). Importantly, the impact of C-terminus swapping was also evidenced in the receptor recycling study ( Figure 5E ,F).
Indeed, the hV 1b R-CterV 2 R chimera was retained longer in the cell, with only 43% AE 5% of receptor sites at the plasma membrane after 30 minutes as compared to 100% AE 7% for hV 1b R-WT. At 120 minutes, we observed 105% AE 6% sites at the plasma membrane and 129% AE 11% for hV 1b R-CterV 2 R and hV 1b R-WT, respectively.
The hV 2 R-CterV 1b R behaved similarly to hV 1b R with 84% AE 14% of receptor sites at the plasma membrane after a 30-minute recycling period compared to 34% AE 6% for hV 2 R-WT. At 120 minutes, 134% AE 26% of receptor sites for hV 2 R-CterV 1b R receptors were at the plasma membrane compared to 50% AE 5% for hV 2 R-WT.
Together, these data clearly demonstrate that the C-terminus of hV 1b R constitutes the fundamental determinant for trafficking (arrestin binding, internalization and recycling kinetics).
1.5 | Crucial role of the hV 1b R C-terminus 368-388 region in the internalization and arrestin interaction
To determine which regions of the hV 1b R C-terminus is potentially responsible for arrestin-dependent functions, different truncated versions of the receptor were constructed. These mutants are depicted in Table 5 and were generated on the basis of different potential protein kinase phosphorylation clusters. hV 1b R-Δ409, hV 1b R-Δ388 and hV 1b R-Δ368 correspond to receptors in which the regions 409-424, 388-424 and 368-424 in the hV 1b R C-terminus were deleted, respectively. These constructs were produced either with free C-terminus or tagged with RLuc for BRET measurements. Functionally, all novel mutants kept the same binding properties and capacity to couple to G-protein/Ca 2+ signaling pathways as hV 1b R although their expression level was decreased. To evaluate β-arrestin recruitment by the receptors using BRET, similar receptor expression levels were selected for each construct (from 0.2 to 0.8 pmol/mg; Table 6 ). By The values are expressed as the mean AE SEM of 3 to 5 experiments in triplicate performed using the AVP agonist contrast to hV 1b R-Rluc, hV 1b R-Δ409-Rluc and hV 1b R-Δ388-Rluc, the truncated mutant hV 1b R-Δ368-Rluc exhibited a reduced capacity to interact with either β-arrestin-1 YFP or β-arrestin-2-YFP ( Figure 6A ).
Consistently, 6Myc-hV 1b R-Δ368 failed to co-immunoprecipitate both β-arrestin-1-Flag and β-arrestin-2-Flag ( Figure 6B ). On the contrary, 6Myc-hV 1b R-Δ388 was still able to maintain its interaction with the 2 β-arrestins as 6Myc-hV 1b R-WT did. Based on BRET and coimmunoprecipitation approaches, the 368-388 region of the hV 1b R appears critical for the interaction with arrestins. In agreement with the arrestin-receptor interaction patterns, the internalization rate of hV 1b R-WT and hV 1b R-Δ388 were similar whereas one of the hV 1b R-Δ368 was strongly reduced but still present ( Figure 6C and Table 6 ). The rate of internalization corresponds to the combination between internalization, export and recycling of receptors. As the C-terminus is also involved in receptor export, 25 the measured rate for the truncated mutant, hV 1b R- 1.6 | Phosphorylation-independent trafficking of hV 1b R
Since hV 1b R interacts with different kinases, namely PKC and GRK5 via its C-terminus 26 suggesting that hV 1b R is phosphorylated, we investigated the role of potentially phosphorylatable serine and threonine residues present in the 368-388 region of hV 1b R on the receptor trafficking. Thus, we constructed 3 novel mutants by replacing serine and threonine clusters by alanines. Indeed, hV 1b R-S4A comprised the 4 S368A, S371A, S373A and S374A mutations and hV 1b R-S5A the 5 T377A, T378A, T381A, S383A and S384A mutations. The hV 1b R-S9A mutant combined the mutations of both hV 1b R-S4A and hV 1b R-S5A (Table 7) . These mutants were generated either as untagged or Rluc-tagged for BRET measurements and they all displayed similar properties as compared to hV 1b R-WT regarding AVP binding and Ca 2+ signaling (Table 8) .
We first evaluated the arrestin recruitment properties of the 3 mutants by BRET. By contrast to the truncated receptor hV 1b R-Δ368-Rluc, the Rluc-tagged hV 1b R-S4A, hV 1b R-S5A and hV 1b R-S9A
were all able to interact with β-arrestin-1-YFP with similar efficiency and kinetics as hV 1b R-Rluc ( Figure 7A ). In the internalization assay, hV 1b R-S9A behaved similarly to the hV 1b R-WT. After 20 minutes of ligand exposure, the remaining surface receptor sites were equivalent for both constructs (41% AE 2%) with identical internalization kinetics t 1/2 of 1.9 AE 0.7 and 1.7 AE 0.3 minutes for hV 1b R-S9A and hV 1b R-WT, respectively ( Figure 7B and Table 8 ). Moreover, the 3 mutants recycled in a way similar to hV 1b R-WT ( Figure 7C and Table 8 ). Altogether, our data indicate that whereas the 368-388 region is a major determinant for hV 1b R-β-arrestin interaction and receptor internalization, the serine and threonine residues expected to be phosphorylated in the C-terminus domain do not play a role either in arrestin recruitment, or in receptor internalization.
| hV 1b R-promoted arrestin-dependent MAPK activation
In previous studies, hV 1b R has been shown to stimulate MAPK pathway. 15, 16 Since GPCR-mediated MAPK activation involves both G protein-dependent pathway and receptor internalization, we investigated the potential link between hV 1b R trafficking and G For the statistical analysis by student test, we compared constructions data either to hV 1b R-WT or 6Myc-hV 1b R as indicated: *P < .05; **P < .01; ***P < .001; no indication means no significant difference.
a The plasmid quantity corresponds to the amount of coding vectors per 10 million cells electropored during the transfection.
b The values are expressed as the mean AE SEM of 3 to 5 experiments in triplicate performed using the AVP agonist 3 H-labeled AVP as the radioligand.
c Kd, affinity of the agonist AVP for the receptor.
d Bmax, maximum binding of the ligand AVP for the receptor, expressed as pmol of receptor per mg of total membrane protein.
e EC 50 s in this column indicate the molar concentrations of the agonist AVP that produce 50% of the maximal effect (calcium mobilization) for the receptors.
f Emax, maximal efficiency of the ligand AVP for the chimeric or mutant receptor, expressed as % of the maximal AVP effect of the wild-type hV 1b receptor (for 6Myc-hV 1b R) or 6Myc-hV 1b R for truncated mutants for calcium mobilization. (Table 9) . These results are illustrated in the Figure 8A . Kinetics profiles were similar for both receptors, with a maximal activation between 3 and 7 minutes. For longer times (between 7 and 30 minutes), a rapid decrease was observed. These data strongly suggest that direct interaction of arrestins with the hV 1b R probably plays a minor role for MAPK activation. FIGURE 5 Effects of hV 1b R/hV 2 R C-terminus swapping on kinetics of arrestin recruitment, receptor internalization and recycling in tsA-201 cells. Real-time BRET experiments for measuring arrestin recruitment were performed using tsA-201cells co-transfected with β-arrestin-1-YFP and either hV 1b R-Rluc ( ) or hV 1b R-CterV 2 R-Rluc ( ) (A), or with β-arrestin-1-YFP and either hV 2 R-Rluc ( ) or hV 2 R-CterV 1b R-Rluc ( ) (B). Cells were incubated at 37 C with coelenterazine-h and 1 μM AVP. Internalization time courses for hV 1b R-WT ( ) and hV 1b R-CterV 2 R ( ) (C), or hV 2 R-WT ( ) and hV 2 R-CterV 1b R ( ) (D) were recorded for different periods of time using a 100 nM AVP stimulation in complete medium at 30 C. Finally, recycling of hV 1b R-WT ( ) and hV 1b R-CterV 2 R ( ) (E), or hV 2 R-WT ( ) and hV 2 R-CterV 1b R ( ) (F) was analyzed (similar to Figure 1 ). For internalization and recycling studies, the remaining maximal plasma membrane sites (Bmax) was determined by 3 [H]AVP labeling at 4 C and Scatchard analysis. Results are expressed as the mean AE SEM of percentage of control conditions from at least 3 independent experiments. For each condition, a statistical analysis between chimeric constructs hV 1b R-CterV 2 R and hV 2 R-CterV 1b R, and hV 1b R-WT (*) or hV 2 R-WT ( * ) as controls respectively was done: *P < .05, **P < .01, ***P < .001 and no indication means no significant difference The plasmid quantity corresponds to the amount of coding vectors per 10 million cells electropored during the transfection.
b
The values are expressed as the mean AE SEM of 3 to 5 experiments in triplicate performed using the AVP agonist
To confirm that arrestins could play a role in ERK signaling of the hV 1b R, we proceeded to a second type of experiment using specific siRNA to invalidate β-arrestins 1 and 2. To calibrate our system, we compared the hV 1b R-induced MAPK activation to that stimulated by 2 receptors taken as references, the hV 2 R and the β 2 adrenergic receptor (β2AR).
Indeed, β-arrestins were previously demonstrated to be essential for the ERK phosphorylation induced by these 2 receptors. 11, 27 In tsA cells, we showed that in conditions where arrestin expression was decreased by 50% ( Figure 8B ), we were able to measure a significant 38% inhibition of MAPK activation under AVP stimulation of the hV 1b R. A similar inhibition was obtained under AVP stimulation of hV 2 R (37%) and was even more pronounced under isoproterenol stimulation of β 2 AR (80%) ( Figure 8C ,D).
These effects were obtained with cells expressing similar receptor expression levels in different conditions (Table 9 ). These data clearly demonstrate that arrestins play a role in hV 1b R-induced MAPK activation.
| hV 1b R-promoted G protein-independent MAPK activation
We then studied whether hV 1b R-induced MAPK activation is dependent or not on the different types of G proteins. We first addressed the potential role of Gq protein in MAPK activation. The hV 1b R-WT expressing tsA cells were pretreated with 10 μM BIM-46187, an inhibitor for Gq proteins 28, 29 and stimulated with AVP (10 and 100 nM). As shown in Figure 9A ,B, although the basal activity was significantly increased, preincubating the cells with BIM-46187 did and hV 1b R truncated receptors was done: *P < .05; **P < .01; ***P < .001 and no indication means no significant difference not inhibit the capacity of AVP to stimulate MAPK phosphorylation.
In order to verify that BIM-46187 efficiently inhibited Gq-protein activity, we simultaneously evaluated its effect on inositol phosphate (IP) signaling, the major G-protein pathway activated by hV 1b R. As demonstrated in Figure 9C , BIM-46187 completely inhibited the AVP-induced IP production. These data clearly demonstrate that hV 1b R-stimulated MAPK activation is Gq protein-independent.
To address the potential role of Gi/o and Gs in ERK phosphorylation pathway, we used PTX to inhibit Gi/o and, as previously demonstrated by Levis and Bourne or by Bouvier's group, 11, 30 we used Cholera Toxin (CTX) to downregulate Gs activity. TsA cells transfected with hV 1b R-WT were treated for 16 hours with 100 ng/mL PTX or 300 ng/mL CTX. Using PTX, we showed no inhibitory effect.
To validate the assay and as a positive control, we used the δ-opioid receptor for which associated ERK phosphorylation pathway is known to be Gi/o dependent. 11 In the presence of 1 μM of the opioid ligand DPDPE, we showed that PTX induced a complete inhibition ( Figure 9D ,E). These data suggest that Gi/o is not involved in hV 1b R-induced ERK phosphorylation pathway.
To determine a potential Gαs involvement, we assessed the effect of downregulating this G-protein subunit by sustained CTX treatment. Indeed, prolonged treatment with CTX, which blocks Gαs in a GTP-bound state and inhibits its GTPase intrinsic activity, leads to a significant downregulation of Gs after 16 hours. 11 In these conditions, we monitored cAMP production in tsA cells expressing the prototypical Gs-coupled hV 2 R. cAMP production was dramatically impaired proving the efficacy of the CTX treatment in these cells ( Figure 9F ). By contrast, MAPK activation upon hV 1b R stimulation with AVP was not significantly inhibited in the presence of CTX ( Figure 9D ,E). Because CTX impacts the level of receptors addressed to the cell surface, results were normalized to the number of receptor ( Figure 9E ). In conclusion, Gq, Gi/o and Gs are not involved in hV 1b Rinduced ERK.
| hV 1b R-stimulated Src-dependent MAPK activation
Since we demonstrated that G proteins were not involved in hV 1b Rmediated MAPK activation, we searched for other potential signaling proteins that may link the hV 1b receptor activation to this signaling pathway. Potential candidates were PKC, phosphatidylinositol 3-kinase (PI3K) and Src kinase. 31 The tsA cells transfected with hV 1b -WT receptor were stimulated with AVP (10 and 100 nM) in the presence of 10 μM of PP2 Src-specific inhibitor or its related inactive PP3 compound. As shown in Figure 10A ,B, PP2 induced a significant decrease in MAPK phosphorylation while PP3 did not. As a negative control, the 2 compounds had no effect on hV 1b R-mediated IP accumulation upon stimulation with increasing concentrations of AVP
showing Src specificity toward MAPK signaling ( Figure 10C ). Similar levels of hV 1b R binding sites were expressed in control and treated (PP2 or PP3) cells (Table 9 ). In the stable hV 1b R-AtT20 cell line, we confirmed, using a Src inhibitor, the specific inhibition of MAPK phosphorylation and the implication of Src kinase family in this process ( Figure 12A,B) . To confirm the involvement of Src, we also examined a putative interaction between hV 1b R and Src. As illustrated in Figure 10D , endogenous Src obtained from tsA cell lysates was efficiently co-immunoprecipitated with 6Myc-tagged hV 1b R in basal con- First, we have shown that hV 1b R could be internalized and recycled very rapidly upon AVP stimulation according to a typical type A trafficking family mechanism-like for hV 1a R. This is in contrast to the hV 2 R which belongs to type B family characterized by slow internalization and long-lasting recycling kinetics. 7 Using a double KO β-arrestin-1/2 MEF cell line, we evidenced that arrestins were fundamental for this process because no internalization of hV 1b R was For the statistical analysis by student test, we compared constructions data either to hV 1b R-WT as indicated:
*P < .05; **P < .01; ***P < .001; no indication means no significant difference.
a
The plasmid quantity corresponds to the amount of coding vectors per 10 million cells electropored during the transfection.
The values are expressed as the mean AE SEM of 3 to 5 experiments in triplicate performed using the AVP agonist measured in their absence. Based on BRET and co-IP experiments, we also investigated the kinetics of hV 1b R-arrestin interactions and we concluded that the hV 1b R behaves in a particular way being able to directly interact with both β-arrestin-1 and 2 with equivalent kinetics and EC 50 s by contrast to other type A receptors that preferentially interact with β-arrestin-2.
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For most GPCRs, including the hV 2 R, the cytoplasmic C-terminus has been shown to play an important role in receptor internalization. [33] [34] [35] [36] This role has been related to its phosphorylation level by GPCR kinases (GPCRK) allowing its binding to arrestins for receptor endocytosis via clathrin-coated pits. Exchanging hV 1b R and hV 2 R C-termini to generate hV 1b R-CterV 2 R and hV 2 R-CterV 1b R chimeras completely reversed their trafficking patterns. In conclusion, the hV 1b R C-terminus plays a major role in arrestin binding and controls the receptor internalization-recycling profiles. These data are similar to those published by Innamorati et al 7 In the literature, the correlation between receptor phosphorylation and arrestin recruitment is puzzling. For instance, proteaseactivated receptor (PAR-1), substance P and leukotriene B4 receptors as well as FSH receptor constitute examples of receptors whereby arrestin binding is independent of receptor phosphorylation. 37, 38 The receptor-arrestin interaction is proposed to be mediated by 2 structural elements present on the arrestin structure: first, an interaction of the activation sensor of arrestin with the active conformation of the receptor itself; second, an interaction of the phosphate sensor of arrestin with the phosphorylated receptor. 39 As the constitutively active R175E-arrestin mutant can still bind to the unphosphorylated rhodopsin receptor, 40 we could consider by homology that the arrestin-activation sensor itself could be sufficient to promote a functional hV 1b R-arrestin complex interacting essentially via the unphosphorylated 368-388 region to induce a related internalization process. This is in agreement with considering hV 1b R as a class A receptor, for which arrestin interaction is much more labile than for class B receptors, such as V 2 R. For class B GPCR, the presence of phosphorylated residues is crucial for long-lasting arrestin interaction and slow recycling.
The trafficking and signaling pattern of hV 1b R is puzzling particularly its associated MAPK activation. Based on our results, this signaling pathway involves arrestins and the Src kinase family but not G proteins. Classically, a GPCR can activate ERK phosphorylation through 2 main pathways. The first pathway is related to G-protein activation followed by transduction by Gβγ subunits and/or kinases that depend on second messengers (PKA, PKC, PI3 kinase for instance). 31 The second pathway involves β-arrestins that participate in G-protein uncoupling and mediate endocytosis of the receptor. 41 In the present study, AVP stimulation of hV 1b R activates ERK phosphorylation as previously shown. 15, 16 However, using different tools such as G-protein inhibitors (BIM-46187, PTX and CTX), we suggest that G proteins do not play a role in this pathway. hV 1b R behaves similarly to 5-Hydroxytryptamine-4 receptor (5-HT 4 R), 42 and β 2 AR at high isoproterenol concentrations, 43 activating the ERK pathway independently from G proteins. By contrast, hV 1b R-stimulated ERK phosphorylation is still dependent on arrestins. Indeed, we showed that the use of siRNA against β-arrestin-1/2 revealed a partial inhibition of hV 1b R-induced MAPK activation in tsA cells indicating that arrestin is involved in this process. As the non-interacting arrestin hV 1b R mutant (hV 1b R-Δ368) was still able to induce MAPK activation with similar kinetics as that of the WT, we suggest that the direct receptor-arrestin interaction is not responsible for the arrestin role in ERK phosphorylation. Rather, other proteins may be involved to mediate this signaling and we report here that hV 1b R activation of ERK phosphorylation requires the nonreceptor tyrosine kinase Src family. Similarly, Src is also involved in 5-HT 4 R-stimulated ERK pathway. 42 In addition, V 2 R-activated ERK pathway acts upstream of the β-arrestin engagement through a Src-dependent metalloproteinase and insulin-like growth factor receptor-mediated signal. 20 We evidenced that Src belongs to the receptor complex and dis- From our study, we propose that, in basal conditions, Src is constitutively associated to the hV 1b R complex at the plasma membrane whereas arrestin is present in the cytoplasm. Upon vasopressin stimulation, arrestin interaction with the receptor leads to its internalization in endosomes and to the physical dissociation of the receptor from Src which remains at the plasma membrane. This type of mutual exclusion has yet to be shown, for instance, for β-arrestin-1 and Gq protein toward the purified GHS-R 1a ghrelin receptor. 44 We suggest that hV 1b R is coupled to at least 3 signaling pathways: Upon AVP stimulation, the receptor activates Gq known to modulate ACTH secretion from pituitary corticotroph cells. 45 In parallel, the recruitment of arrestins controls the receptor trafficking and regulates its desensitization. Finally, hV 1b R activates the MAPK pathway independently from G proteins but via an arrestin-and Src-dependent process ( Figure 13 ). As ERK1/2 signaling is critical for multiple cellular processes such as proliferation, differentiation, survival and migration, 46 Src appears as a new important target that could be explored in relevant models like the primary corticotroph cells. In this context, the development of biased agonists specific for this latter pathway may be useful to better understand the contribution of the different hV 1b R signaling pathways in regulating stress, depression and anxiety. Results are expressed as the mean AE SEM to control conditions from at least 3 independent experiments. For each condition, a statistical analysis between hV 1b R-WT as a control and hV 1b R truncations or mutants was done: *P < .05; **P < .01 and ***P < .001; no indication means no significant difference The ps-6Myc-hV 1b R-Δ368 and ps-6Myc-hV 1b R-Δ388 (named 6Myc-hV 1b R-Δ368 and 6Myc-hV 1b R-Δ388) used for co-immunoprecipitation experiments were generated by introducing a stop codon in ps-6Myc-hV 1b R-N1 plasmid as a template at 368th and 388th positions of the sequence. Ps-6Myc-hV 1b R-N1 was derived from the ps-EGFP-6Myc-hV 1b R-WT vector. 25 The EGFP-deleted version of this vector (ps-6Myc)
| MATERIALS AND METHODS

| Materials
was generated by deletion of the EGFP sequence and in-frame insertion of a linker. 25 We used the primers 5 0 -P-GCGCCGGCGGCTCTAG-GACGGCAGCCTCTC-3 0 and 5 0 -P-CCAGCTGCCCGGCCTAGCTCAG-CCTCAGCCTC-3 0 for Δ368 and Δ388, respectively.
The serine mutants of the hV 1b R C-terminus hV 1b R-S4A-(Rluc), hV 1b R-S5A-(Rluc) and hV 1b R-S9A-(Rluc) were generated using the QuikChange Multi-Site Directed Mutagenesis Kit (Stratagene).
Reaction conditions were applied as described in the manufacturer protocol. The reaction mix included the pRK5-V 1b R-WT or pcDNA3- The chimeras, hV 1b R-CterV 2 R and hV 2 R-CterV 1b R, were generated by in-frame fusion of the N-terminal part of one receptor subtype (hV 1b R-WT or hV 2 R-WT, up to the 2 palmitoylated cysteines), to the C-terminal part of the other receptor subtype (residues Ala 343-Ser 371 for hV 2 R-WT, and Gly 357-Phe 424 for hV 1b R-WT), respectively.
Thus, HindIII restriction site was introduced in the hV 1b R-WT sequence just before the 2 palmitoylated cysteines, whereas the same restriction site was already present at the corresponding site in hV 2 R-WT. The
QuikChange Site-Directed Mutagenesis Kit (Stratagene) and reaction conditions described therein were used. PRK5-V 1b R-WT was used as template and 2 primers were added to the reaction mix, forward: 5 0 -GTTACCGCGGCCCCTGCGAAGCTTGGCCTGCTGTGGG-3 0 and reverse: After creating the non-tagged chimeras, BamHI sites were introduced upstream of the first residue and downstream of the final residue in order to be subcloned them in the pcDNA3-Rluc vector, in frame and upstream to the RLuc tag. The primers couples used were:
forward V 1b R-CterV 2 R 5 0 -GCAACGCGGATCCGATGGATTCTGGGCC-TCTGTG-3 0 and reverse V 1b R-CterV 2 R 5 0 -GCAACGCGGATCCCCC-
All sequences were verified by direct DNA sequencing (MWG Eurofins, Germany and Cogenics, France).
| Cell culture and transfection
The were cultured at 37 C in 5% CO 2 in DMEM containing 10% fetal calf serum (FCS) and 100 units/mL penicillin, 100 μg/mL streptomycin. were harvested using trypsin, transiently transfected with plasmid DNA using either a well-described electroporation or lipofectamin protocol and grown either 24 or 48 hours before experiment. Immunoblotting of different conditions with β-arrestin 1/2 and GAPDH antibodies were followed by densitometry. Data are expressed as percent of siRNA control conditions of ratio arrestin/ GAPDH in each condition. In C, MAP kinase phosphorylation, expressed in ratio 665/620 for the different receptors, in siRNA control or siRNA β-arrestin 1/2 conditions, after 7 minutes at 37 C, in the absence ( ) or in the presence ( ) of 1 μM AVP (hV 1b R-WT, hV 2 R-WT) or 1 μM Isoproterenol and 10 μM ascorbic acid (ps-Mychβ 2 AR). In (D), data of (C) are presented as percent of specific ligandinduced ratio 665/620 with siRNA control conditions as 100% for each receptor in siRNA control ( ) or siRNA β-arrestin 1/2 ( ) conditions. Data correspond to the mean AE SEM of n = 6 experiments. Statistical analysis was done in A between hV 1b R-WT and hV 1b R-Δ368 and in (B-C-D) between siRNA control conditions and siRNA β-arrestin 1/2 with *P < .05, **P < .01 and ***P < . A statistical analysis of basal and AVP-stimulated conditions as a control against BIM-46187 conditions was done: *P < .05; **P < .01 and ***P < .001. C, AVP dose-response curves for inositol phosphates production in the absence ( ) or in the presence of 10 μM BIM-46187 ( ) from one experiment representative of at least 3 independent experiments, each performed in triplicate. Gi/o and Gs proteins: MAP kinase phosphorylation was measured using tsA-201cells transiently transfected with hV 1b R-WT or SNAP-Flag-h-δOR and stimulated 7 minutes at 37 C with 1 μM AVP (hV 1b R-WT) or DPDPE (SNAP-Flag-h-δOR). D, Data expressed as ratio 665/620 with buffer ( ) or 1 μM ligand ( ) in the absence (control) or in the presence of a 16 hours incubation with 100 ng/mL PTX or 300 ng/mL CTX, (E) data are presented in percent of control conditions of specific ligand-induced ratio 665/620 in each condition normalized to the receptor expression with ligand alone ( ) or in the presence of PTX ( ) or CTX ( ). F, cAMP production was measured using tsA-201cells transiently transfected with 0.1 ng hV 2 R-WT stimulated 30 minutes with 1 μM AVP in the absence control ( ) or in the presence of 16 hours incubation with 300 ng/mL CTX ( ), expressed as specific AVP-induced cAMP production (nM) in each condition. Data correspond to the mean AE SEM of 3 or 4 independent experiments. Statistical analysis was done with *P < .05; **P < .01 and ***P < . Experiments were repeated at least 3 times on different cultures.
| [ 3 H]AVP binding assays
| cAMP and IPs accumulation assays
Results were plotted using GraphPad Prism 4. 
| BRET measurements
| siRNA Western blotting
For quantifying arrestin invalidation with siRNA, we performed SDS-PAGE in 10% polyacrylamide gels (20 μg of proteins for each sample).
For western blot analysis onto nitrocellulose, we used 1/1000 of β-arrestin 1/2 antibodies and 200 ng/mL GAPDH antibodies followed by 1/2000 of anti-rabbit-HRP and anti-mouse-HRP, respectively. We revealed luminescence with the ECL reagent on the Chemidoc Touch (Biorad) and quantified immunoreactive bands by densitometry with the Image Lab software. For each point, we determined the ratio (R) β-arrestin 1/2/GAPDH and expressed as percent of siRNA control conditions using the following formula: (R siRNA β-arrestin 1/2 /R siRNA control ) × 100, where R siRNA β-arrestin 1/2 and R siRNA control corresponds to the ratios observed in siRNA β-arrestin 1/2 and siRNA control conditions, respectively.
| Confocal microscopy and image analysis
AtT20 cells stably expressing hV 1b R-EGFP were produced 21 
| Statistical analysis
Results are reported as group means AE SEM from at least 3 independent experiments, each performed in triplicate. Student's t test gave us the statistical significance of differences between independent groups with no indication for non significant difference, *P < .05, **P < .01 and ***P < .001. 
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